Chinese Journal of Clinical Pharmacology and Therapeutics ›› 2011, Vol. 16 ›› Issue (5): 590-594.
Previous Articles Next Articles
DENG Xiao-lan, LI Hui, JING Xian, TIAN Ying-ying, LV Pei-yu, OUYANG Dong-sheng
Received:
2011-04-27
Revised:
2011-05-20
Published:
2011-07-08
CLC Number:
DENG Xiao-lan, LI Hui, JING Xian, TIAN Ying-ying, LV Pei-yu, OUYANG Dong-sheng. Recent progress of aldose reductase in non-diabetic disease[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2011, 16(5): 590-594.
[1] 谷娟, 严谨, 吴卫华, 等. 醛糖还原酶的研究进展[J]. 中南大学学报:医学版,2010,35(4): 395-400. [2] 王俊杰, 康桢, 李茯酶, 等. 醛糖还原酶:心肌缺血损伤干预的新靶点[J]. 国际病理科学与临床杂志, 2007, 27 ( 3 ) : 211-213. [3] Anil Kumar P, Bhanuprakash Reddy G. Focus on molecules: aldose reductase[J]. Exp Eye Res, 2007,85(6):739-740. [4] Fournier B, Bendeifel E, Guillot B, et al. Charge density and electrostatic interactions of fidarestat, an inhibitor of human aldose reductase[J]. J Am Chem Soc, 2009, 131(31):10929-10941. [5] Ramana KV, Srivastava SK. Aldose reductase: A novel therapeutic target for inflammatory pathologies[J]. Int J Biochem Cell Biol, 2010, 42(1):17-20. [6] 欧阳冬生, 黄琪, 刘黎, 等. 醛糖还原酶在糖尿病并发症和心血管病变中的作用[J]. 中国现代医学杂志, 2008, 18(17):2506-2509. [7] Liew G, Klein R, Wong TY. The role of genetics in susceptibility to diabetic retinopathy[J]. Int Ophthalmol Clin, 2009, 49(2):35-52. [8] Wu JC, Li XH, Wang JB, et al. Glyoxalase I and aldose reductase gene polymorphisms and susceptibility to carotid atherosclerosis in type 2 diabetes[J]. Genet Test Mol Biomarkers, 2011, 15(4):273-279. [9] Uthra S, Raman R, Mukesh BN, et al. Diatetic retinopathy: validation study of ALR2, RAGE, iNOS and TNFB gene variants in a south indian cohort[J]. Ophthalmic Genet, 2010, 31(4):244-251. [10] Abhery S, Burdon KP, Laurie KJ, et al. Aldose reductase gene polymorphisms and diabetic retinopathy suscepibility[J]. Diabetes Care, 2010, 33 (8):1834-1836. [11] Prasad P, Tiwari AK, Kumar KM, et al. Association analysis of ADPRT1, AKR1B1, RAGE, GFT2 and PAI-1 gene polymorphisms with chronic renal insufficency among Asian Indians with tpype-2 diabetes[J]. BMC Med Genet, 2010, 11:52. [12] Kariserova K, Srivastava S, Hoetker JD. Redox activation of aldose reductase in the ischemic heart[J]. J Biol Chem, 2006, 281(22):15102-15120. [13] Kaiserova K, Tang XL, Srivastava S, et al. Role of nitric oxide in regulating aldose reductase activation in the ischemic heart[J]. J Biol Chem, 2008, 283(14):9101-9112. [14] Hwang YC, Kaneko M, Bakr S, et al. Central role for aldose reductase pathway in myocardial ischemic injury[J]. FASEB J, 2004, 18(11):1192-1199. [15] Hwang YC, Shaw S, Kaneko M, et al. Aldose reductase pathway mediates JAK-STAT signaling: a novel axis in myocardial ischemic injury[J]. FASEB J, 2005, 19(7):795-797. [16] Ananthakrishnan R, Kaneko M, Hwang YC, et al. Aldose reductase mediates myocardial ischemia-reperfusion injury in part by opening mitochondrial permeability transition pore[J]. Am J Physiol Heart Circ Physiol, 2009, 296(2):H333-341. [17] Iwaka K, Matsuno K, Nishinaka T, et al. Aldose reductase inhibitors improve myocardial reperfusion injury in mice by a dual mechanism[J]. J Pharmacol Sci, 2006, 102:37-46. [18] Keith RJ, Haberzettl P, Vladykovskaya E, et al. Aldose reductase decreases endoplasmic reticulum stress in ischemic hearts[J]. Chem Biol Interact, 2009, 178(1/2/3 ) : 242-249. [19] Rudijanto A. The role of vascular smooth muscle cells on the pathogenesis of atherosclerosis[J]. Acta Med Indones, 2007, 39(2) : 86-93. [20] Tammali R, Saxena A, Srivastava SK, et al. Aldose reductase regulates vascular smooth muscle cell proliferation by modulating G1/S phase transition of cell cycle[J]. Endocrinology, 2010, 151(5) : 2140-2150. [21] Liu X, Shen J, Zhan R, et al. Propeomic analysis of homocysteine induced proliferation of cultured neonatal rat vascular smooth muscle cells[J]. Biochim Biophys Acta, 2009, 1794(2) : 177-184. [22] Gu J, Wang JJ, Yan J, et al. Effects of lignans extracted from Eucommia ulmoides and aldose reductase inhibitor epalrestat on hypertensive vascular remodeling[J]. J Ethnopharmacol, 2010, 133(1) : 6-13. [23] Srivastava S, Vladykovskaya E, Barski OA, et al. Aldose reductase protects against early atherosclerotic lesion formation in apolipoprotein E-null mice[J]. Cir Res, 2009, 105(8): 793-802. [24] Ramana KV, Bhantnagar A, Srivastava SK. Inhibition of aldose reductase attenuates TNF-a-induced expression of adhesion molecules in endothelial cells[J]. FASEB J, 2004, 18(11): 1209-1218. [25] Ramana KV, Fadl AA, Tammali R, et al. Aldose reductase mediates the lipopolysaccharide-induced release of inflammatory mediators in RAW264.7 murine macrophages[J]. J Biol Chem, 2006, 281(44): 33019-33029. [26] Ramana KV, Reddy AB, Tammali R, et al. Aldose reductase mediates endotoxin-induced production of nitric oxide and cytotoxicity in murine macrophages[J]. Free RadIC Biol Med, 2007, 42(8): 1290-1302. [27] Ramana KV, Willis MS, White MD, et al. Endotoxin-induced cardiomyopathy and systemic inflammation in mice is prevented by aldose reductase inhibition[J]. Circulation, 2006, 114(17): 1838-1846. [28] Reddy AB, Srivastava SK, Ramana KV. Aldose reductase inhibition prevents lipopolysaccharide-induced glucose uptake and glucose transporter 3 expression in RAW264.7 macrophages[J]. Int J Biochem Cell Biol,2010, 42 ( 6 ) : 1039-1045. [29] Yadav UC, Ramana KV, Aguilera-Aguirre L, et al. Inhibition of aldose reductase prevents experimental allergic airway inflammation in mice[J]. PLoS One, 2009, 4 ( 8 ) : e6535. [30] Ravindranath TM, Mong PY, Ananthakrishnan R, et al. Novel role for aldose reductase in mediating acute inflammatory responses in the lung[J]. J Immunol, 2009, 183 (12) : 8128-8137. [31] Yadav UC, Srivastava SK, Ramana KV. Understanding the role of aldose reductase in ocular inflammation[J]. Curr Mol Med, 2010, 10(6) : 540-549. [32] Wang C, Yan R, Luo D, et al. Aldo-keto reductase family 1 member B10 promotes cell survival by regulating lipid synthesis and eliminating carbonyls[J]. J Biol Chem, 2009, 284(39) : 26742-26748. [33] Tammali R, Ramana KV, Singhal SS, et al. Aldose reductase regulates growth factor-induced cyclooxy-genase-2 expression and prostaglandin E2 production in human colon cancer cells[J ] . Cancer Res, 2006, 66(19) : 9705-9713. [34] Ramana KV, Tammali R, Srivastava SK. Inhibition of aldose reductase prevents growth factor-induced G1-S phase transition through the AKT/phosphoinositide 3-kinase/E2F-1 pathway in human colon cancer cells[J ] . Mol Cancer Ther, 2010, 9(4):813-824. [35] Tammali R, Reddy AB, Ramana KV, et al. Aldose reductase deficiency in mice prevents azoxymethane-induced colonic preneoplastic aberrant crypt foci formation[J]. Carcinogenesis, 2009, 30(5) : 799-807. [36] Lefranois-Martinez AM, Bertherat J, Val P, et al. Decreased expression of cyclic adenosine monophosphate-regulated aldose reductase (AKR1B1) is associated with malignancy in human sporadic adrenocortical tumors[J]. J Clin Endocrinol Metab, 2004, 89 ( 6 ) : 3010-3019. [37] Plebuch M, Soldana M, Hungerera C, et al. Increased resistance of tumor cells to daunorubicin after transfection of cDNAs coding for anthracycline inactivating enzymes[J]. Cancer Lett, 2007, 255 : 49-56. [38] 何晓峰, 赵晓琴, 刘晓城, 等. 黄芪对左肾静脉狭窄大鼠肾组织病理学与转化生长因子-β1表达的影响[J ] . 医药导报, 2008, 27(5) : 509-510. [39] Zhang Y, Huang P, Jiang T, et al. Role of aldose reductase in TGF-beta1-induced fibronectin synthesis in human mesangial cells [ J ] . Mol Biol Rep, 2010, 37 ( 6 ) : 2735-2742. [40] Huang P, Zhang Y, Jiang T, et al. Aldose reductase is a potent regulator of TGF-β1 induced expression of fibronectin in human mesangial cells[J]. Mol Biol Rep, 2010, 37(7) : 3097-3103. [41] Hasuike Y, Moriguchi R, Hata R, et al. Role of aldose reductase in the peritoneal changes of patients undergoing peritoneal dialysis[J]. Am J Nephrol, 2007, 27(6) : 622-629. [42] Lo ACY, Cheung A, Hung VKL, et al. Deletion of aldose reductase leads to protection against cerebral ischemic injury[J]. J Cereb Blood Flow Metab, 2007, 27(8) : 1496-1509. [43] Yagihashi S, Mizukami H, Ogasawara S, et al. The role of the poyol pathway in acute kidney injury caused by hindlimb ischaemia in mice[J]. J pathol, 2010, 220(5) : 530-541. [44] Obrosova IG, Maksimchyk Y, Pacher P, et al. Evaluation of the aldose reductase inhibitor fidarestat on ischemia-reperfusion injury in rat retina[J]. Int J Mol Med, 2010, 26(1) : 135-142. [45] Hallam KM, Li Q, Ananthakrishnan R, et al. Aldose reductase and AGE-RAGE pathways: central roles in the pathogenesis of vascular dysfunction in aging rats[J]. Aging Cell, 2010, 9(5) : 776-784. [46] Kabututu Z, Manin M, Pointu JC, et al. Prostaglandin F 2a sythase avtivities of aldos-keto reductase 1B1,1B3 and 1B7[J]. J Biochemistry, 2009, 145(2) : 161-168. [47] Bresson E, Boucher-Kovalik S, Chapdelaine P, et al.The human aldose reductase AKR1B1 qualifies as the primary prostaglandin F synthase in the endometrium[J]. J Clin Endocrinol Metab, 2011, 96(1): 210-219. |
[1] | MA Yan, TIAN Gaopeng, SHI Xingwen, SUN Ting, XIE Jingjing, ZHEN Donghu. Correlation between 25(OH)D and metabolically related fatty liver in T2DM population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(9): 1018-1026. |
[2] | HOU Ruiying, GUO Lige, JIAO Weijie, DU Lei, WU Guiyue, ZHAO Xu. Effects of Xiaokeshu recipe on levels of serum inflammatory factors in type2 diabetic rats and its mechanism [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2023, 28(4): 377-382. |
[3] | ZHAI Weiwei, YU Qiaoling, LIU Ping, QIU Bo, WU Huizhen. Research progress of finerenone in the treatment of type 2 diabetes mellitus complicated with chronic kidney disease [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(9): 1067-1074. |
[4] | LU Senlin, LIU Xinyuan, WANG Jili, HUANG Xiaofei. Research progress of virus-mediated gene therapy in type 2 diabetes mellitu [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(7): 800-807. |
[5] | DAI Hongyu, YANG Kun, HU Ruchun, ZHOU Hongmei, MA Peimin, HAO Qian. Duration time and effectiveness of 0.25%ropivacaine for sciatic nerve block in patients with diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2022, 27(11): 1278-1284. |
[6] | WU Yi, FANG Fang, CHEN Ying, Fan Junwei. Influence of donor and recipient CYP3A5 genotype on tacrolimus trough concentrations in the early stage after liver transplantation and its clinical significance [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2021, 26(6): 631-639. |
[7] | XU Yongxia, XIE Mingzhu, GONG Muxue, HUANG Jiaying, ZHAO Li, ZHU Defa. Effects of 25(OH)D on islet β-cells function in the elderly with type 2 diabetes [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(9): 1021-1026. |
[8] | ZHAO Hailing, ZHANG Haojun, ZHAO Tingting, YAN Meihua, DONG Xi, MA Liang, LI Ping. Association between the polymorphism of PNPLA2 gene and the risk of ischemic stroke in type 2 diabetic patients in Chinese Han Population [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(6): 664-669. |
[9] | HUANG Hao, XIAO Fang, JIA Hong, WANG Xiaoshuang, DUAN Yating. miR-138-5p protects β cell function by regulating HIF-1α in gestational diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2020, 25(5): 489-497. |
[10] | YE Shengkai, WEN Jie, LIU Weiping, REN Xia, CHEN Haiying, DU Ying, LI Xue, ZHANG Ru, YU Li, ZHANG Biying. Effects of dapagliflozin on intima-medial thickness of carotid artery in type 2 diabetic mellitus patients [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(7): 814-819. |
[11] | XU Ming, SHEN Zheng. Research progress on the mechanism of traditional Chinese insects' medicine treatment of diabetic neurological complications [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(5): 597-600. |
[12] | LI Zhuqing, JU Yinghui, CHEN Qingqing, MA Keke, LI Weiping. Protective effects of Astragaloside Ⅳ on early kidney damage in diabetes mellitus rats and its mechanisms [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(3): 255-262. |
[13] | ZHANG Chunyan, FAN Xiaodong, QIN Yuan, KONG Wenqiang, ZHOU Chunyang, DU Biao. Markov model to assess long-term effects of teneligliptin in treatment of type 2 diabetes mellitus [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(1): 65-72. |
[14] | SONG Meiqing. Effect of metformin on bone mineral density, insulin resistance and cytokines in type 2 diabetes mellitus patients with primary hypertension [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 694-698. |
[15] | LIU Chang, JIANG Daoli, LIU Xiaofang, XU Jia, WANG Lijue, WANG Qian, XU Ling, FANG Yi. Establishment of rat model of type 2 diabetes induced by streptozotocin combined with cerebral ischemic reperfusion injury [J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(5): 518-525. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||